/RZLT
RZLT Stock - Rezolute, Inc.
Healthcare|BiotechnologyNASDAQ
$1.77-4.32%
$0.08 (-4.32%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+335.6%upside
Target: $7.71
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RZLT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.75 – $1.79
TARGET (TP)$7.71
STOP LOSS$1.63
RISK/REWARD1:42.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.22
52W High$11.46
52W Low$1.07
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-13,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-79,894,000 | $-70,423,000 | $-55,990,000 | $-41,843,000 | $-22,894,000 |
| Net Income | $-74,412,000 | $-68,459,000 | $-51,787,000 | $-41,060,000 | $-20,902,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.98 | $-1.33 | $-1.01 | $-2.26 | $-2.72 |
Company Overview
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
67%
Hold / Neutral
3
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish3 Neutral/Bearish
Price Targets
$10
Average Target
↑ 446.1% Upside
Now
$1
Low
$10
Average
$17
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Craig Hallum | Downgrade | Hold | $2 |
| December 11th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| December 11th 2025 | Wedbush | Downgrade | Neutral | $1 |
| November 5th 2024 | Wedbush | Initiation | Outperform | $12 |
| August 27th 2024 | Guggenheim | Initiation | Buy | $11 |
| July 17th 2024 | BTIG Research | Initiation | Buy | $13 |
| June 4th 2024 | Craig Hallum | Initiation | Buy | $14 |
| April 9th 2024 | Maxim Group | Initiation | Buy | $8 |
| August 2nd 2022 | Canaccord Genuity | Resumed | Buy | $17 |
| June 15th 2022 | Cantor Fitzgerald | Initiation | Overweight | $9 |
Earnings History & Surprises
RZLTBeat Rate
56%
Last 18 quarters
Avg Surprise
+7.8%
EPS vs Estimate
Beats / Misses
10/6
2 met exactly
Latest EPS
$-0.18
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.27vs$-0.27
Q2 24
0.0%
$-0.34vs$-0.34
Q3 24
-46.7%
$-0.44vs$-0.30
Q4 24
+37.1%
$-0.22vs$-0.35
Q1 25
+33.3%
$-0.22vs$-0.33
Q2 25
-22.7%
$-0.27vs$-0.22
Q3 25
-13.0%
$-0.26vs$-0.23
Q4 25
+33.3%
$-0.18vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.27 | $-0.18 | +33.3% | ✓ BEAT |
Q3 2025 | Sep 17, 2025 | $-0.23 | $-0.26 | -13.0% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q1 2025 | Feb 12, 2025 | $-0.33 | $-0.22 | +33.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.35 | $-0.22 | +37.1% | ✓ BEAT |
Q3 2024 | Sep 19, 2024 | $-0.30 | $-0.44 | -46.7% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.34 | $-0.34 | 0.0% | = MET |
Q1 2024 | Feb 13, 2024 | $-0.27 | $-0.27 | 0.0% | = MET |
Q4 2023 | Nov 13, 2023 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q3 2023 | Sep 14, 2023 | $-0.34 | $-0.25 | +26.5% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.31 | $-0.30 | +3.2% | ✓ BEAT |
Q1 2023 | Feb 10, 2023 | $-0.33 | $-0.26 | +21.2% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.31 | $-0.19 | +38.7% | ✓ BEAT |
Q3 2022 | Sep 15, 2022 | $-0.34 | $-0.37 | -8.8% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.86 | $-0.65 | +24.4% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $-0.77 | $-0.80 | -3.9% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.90 | $-0.92 | -2.2% | ✗ MISS |
Q3 2021 | Sep 15, 2021 | $-0.82 | $-0.78 | +4.9% | ✓ BEAT |
Latest News
Guggenheim Maintains Buy on Rezolute, Lowers Price Target to $6
➖ NeutralBenzinga•Dec 12, 2025, 01:41 PM
HC Wainwright & Co. Maintains Buy on Rezolute, Lowers Price Target to $5
➖ NeutralBenzinga•Dec 12, 2025, 11:27 AM
XOMA Royalty Corporation shares are trading lower after partner Rezolute reported negative trial results for its partnered product, Ersodetug.
📉 NegativeBenzinga•Dec 11, 2025, 06:55 PM
Rezolute plunges as lead asset fails in late-stage trial
📉 NegativeSeeking Alpha•Dec 11, 2025, 01:23 PM
Rezolute shares are trading lower after the company said its Phase 3 sunRIZE study of Ersodetug in congenital hyperinsulinism did not meet the primary or key secondary endpoint.
📉 NegativeBenzinga•Dec 11, 2025, 12:46 PM
Trading Halt: Halt status updated at 7:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 11, 2025, 12:15 PM
Rezolute's Topline Data From Its Phase 3 sunRIZE Study Evaluating Ersodetug In Patients With Congenital Hyperinsulinism Did Not Meet The Primary Or Key Secondary Endpoint
📉 NegativeBenzinga•Dec 11, 2025, 12:09 PM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 11, 2025, 11:55 AM
Rezolute Files For Mixed Shelf Offering, Size Not Disclosed
➖ NeutralBenzinga•Dec 5, 2025, 10:33 PM
BTIG Reiterates Buy on Rezolute, Maintains $17 Price Target
📈 PositiveBenzinga•Nov 20, 2025, 01:02 PM
Rezolute Q1 EPS $(0.18) Beats $(0.26) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 10:11 PM
Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $17
📈 PositiveBenzinga•Oct 29, 2025, 04:02 PM
Guggenheim Reiterates Buy on Rezolute, Maintains $15 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 12:47 PM
Maxim Group Maintains Buy on Rezolute, Raises Price Target to $20
📈 PositiveBenzinga•Sep 19, 2025, 04:49 PM
BTIG Reiterates Buy on Rezolute, Maintains $17 Price Target
📈 PositiveBenzinga•Sep 18, 2025, 09:40 AM
Rezolute Q4 EPS $(0.26) Misses $(0.22) Estimate
📉 NegativeBenzinga•Sep 17, 2025, 08:08 PM
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
📈 PositiveBenzinga•Sep 3, 2025, 11:12 AM
Rezolute Secures FDA Alignment On Streamlined Phase 3 upLIFT Trial Of Ersodetug For Tumor Hyperinsulinism; Study Simplified To 16-Patient Open-Label Design, Supported By sunRIZE Confirmatory Data Expected Dec 2025
📈 PositiveBenzinga•Sep 2, 2025, 10:17 AM
Rezolute stock rises after pricing $90M securities offering
📈 PositiveSeeking Alpha•Apr 23, 2025, 01:20 PM
Rezolute prices $90M of common stock, pre-funded warrants; shares soar
📈 PositiveSeeking Alpha•Apr 23, 2025, 01:14 PM
Frequently Asked Questions about RZLT
What is RZLT's current stock price?
Rezolute, Inc. (RZLT) is currently trading at $1.77 per share. The stock has moved -4.32% today.
What is the analyst price target for RZLT?
The average analyst price target for RZLT is $7.71, based on 1 analyst.
What sector is Rezolute, Inc. in?
Rezolute, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RZLT's market cap?
Rezolute, Inc. has a market capitalization of $0.16 billion, making it a small-cap company.
Does RZLT pay dividends?
No, Rezolute, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to RZLT for comparison